[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-post-stroke-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-post-stroke-pain":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,65,97,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100637570","treatment-of-post-stroke-central-pain-100637570",false,"NCT07593313","Treatment of Post-Stroke Central Pain","Efficacy and Safety of Short-Term Spinal Cord Stimulation Combined With Pharmacotherapy for Central Post-Stroke Pain: A Single-Center, Randomized, Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of central post-stroke pain (CPSP) according to the International Association for the Study of Pain (IASP) criteria\n* Clear history of stroke confirmed by cranial CT or MRI\n* Pain occurring after stroke and distributed in body parts corresponding to central nervous system injury\n* Pain with neuropathic characteristics (e.g., burning sensation, electric shock sensation, needle prick sensation)\n* Pain not explained by other causes\n* Age ≥ 18 years\n* Pain duration ≥ 3 months\n* Baseline pain Numerical Rating Scale (NRS) score ≥ 4 points\n* Complete clinical data with follow-up time ≥ 6 months\n\nExclusion Criteria:\n\n* History of chronic pain before stroke\n* Severe cognitive impairment that prevents cooperation with pain assessment (Mini-Mental State Examination, MMSE \\\u003C 15 points)\n* Contraindications to spinal cord stimulation (SCS), such as coagulation disorders, active infections, or mental diseases that prevent cooperation\n* Malignant tumors or other severe organic diseases with expected survival \\\u003C 1 year","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","To evaluate the short-term analgesic efficacy of stSCS combined with pharmacotherapy compared with pharmacotherapy alone in patients with CPSP, measured by Numerical Rating Scale (NRS) score immediately after treatment.",[26],"Central Post-Stroke Pain","RECRUITING","2026-05-13",{"date":30,"type":31},"2026-05-18","ACTUAL",{"date":33,"type":31},"2024-01-01",{"date":35,"type":20},"2026-08-01",{"name":37,"class":38},"Nanchong Central Hospital","OTHER_GOV",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100454971","thalamic-burst-dbs-for-neuropathic-pain-100454971","NCT05204472","Thalamic-Burst-DBS for Neuropathic Pain","Burst-Deep Brain Stimulation of the Thalamus for Neuropathic Facial Pain and Central Poststroke Pain: a Prospective, Randomized Cross-over Feasibility Trial","Inclusion Criteria:\n\n* Signed informed consent\n* Age 18-75 years\n* Patients suffering from chronic (duration \\> 12 months) unilateral neuropathic pain caused by an ischemic or haemorrhagic cerebral stroke or\n* Patients suffering from chronic (duration \\> 12 months) unilateral neuropathic facial pain due to one of the following causes:\n\n  1. post-herpes-zoster-neuralgia,\n  2. posttraumatic, neuropathic facial pain,\n  3. atypical trigeminal neuralgia after surgical intervention\n* Severe baseline pain intensity (VAS score \\> 6\u002F10) considered as resistant to medication specific to neuropathic pain at sufficient doses and durations (including at least antiepileptics and antidepressants)\n\nExclusion Criteria:\n\n* Significant cognitive impairment (total MOCA score \\\u003C 1.5 standard deviations from age- and education adapted mean values),\n* DSMIV axis I or II psychiatric disorder\n* Relevant psychosocial risk factors (any of): history of other chronic pain syndrome, pain catastrophizing, substance abuse, secondary gain\n* Contra-indication to surgery, anesthesia, or MRI\n* Known or suspected non-compliance or inability to operate the DBS system\n* Woman with childbearing potential\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia. etc. of the subject\n* Participation in another interventional clinical trial within 30 days prior to this trial or during the trial\n* Previous enrollment into the current trial\n* Enrolment of the investigator's family members, employees, and other dependent persons\n* Patients who are planned to undergo diathermy, electroshock therapy or transcranial magnetic stimulation (TMS)\n* Patients with implanted electric devices (i.e. cardiac defibrillator, pacemaker)\n* Patients who are at poor surgical risk (i.e. patients with multiple severe illnesses or active general infections)","75 Years",{"count":49,"type":20},20,[23],"Central post-stroke pain (CPSP) is a neuropathic pain syndrome and one of the major sequelae after ischemic or hemorrhagic cerebral stroke.\n\nRecently, a modified stimulation paradigm has been developed in the field of spinal cord stimulation (SCS) for a variety of neuropathic pain disorders. To date, this stimulation paradigm has not yet been evaluated systematically for deep brain stimulation to treat neuropathic pain disorders.\n\nThe purpose of this clinical investigation is to investigate if Burst-DBS of the thalamus is more effective compared to classical continuous low-frequency stimulation DBS to reduce the subjective pain intensity in patients with chronic neuropathic pain after stroke or in patients with neuropathic facial pain.",[53,54],"Central Post-stroke Pain","Neuropathic Pain","2026-04-30",{"date":57,"type":31},"2026-05-06",{"date":59,"type":31},"2022-09-01",{"date":61,"type":20},"2027-02",{"name":63,"class":64},"Insel Gruppe AG, University Hospital Bern","OTHER",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100608507","effect-of-early-neuromodulation-coupled-with-rehabilitation-on-the-prevention-of-post-stroke-pain-100608507","NCT07202455","Effect of Early Neuromodulation Coupled With Rehabilitation on the Prevention of Post-stroke Pain","ENADA","Inclusion Criteria:\n\n* Age ≥18 years\n* Ischemic or hemorrhagic stroke confirmed by MRI or scanner\n* Lesion(s) in somato-sensory areas (i.e. mainly in: the pons, thalamus, internal capsule, basal ganglia and operculo-insular regions)\n* Sensory and\u002For motor deficit requiring rehabilitation\n* Subacute stage (7 to 45 days post-stroke)\n* No neurological deficit or chronic neuropathic pain prior to stroke\n* No neuropathic pain at inclusion\n* Patient can be followed throughout the study.\n* Information letter read and understood\n* Able to give informed consent to participate in research\n* Affiliation with a social security scheme\n\nExclusion Criteria:\n\n* Contraindication to tDCS (epilepsy\u002Fhistory of epilepsy, intracranial ferromagnetic material or implanted stimulator, acute eczema or irritated skin over the stimulation area)\n* Contraindication to MRI (use of a pacemaker or insulin pump, wearing of a metal prosthesis, intracerebral clip or piercing, claustrophobia)\n* Cognitive or language difficulties preventing comprehension of instructions and\u002For correct clinical assessment\n* Patients participating in another research protocol involving a drug in the 30 days prior to inclusion\n* Drug or psychoactive substance abuse\n* Pregnant or breast-feeding women\n* Patients under guardianship or curatorship, deprived of liberty, safeguard of justice\n* Major depression\n* Patients with Parkinson's disease\n* The presence of pre-existing lesions \\>1.5 cm (maximum diameter) in a cerebral area belonging to the anatomically defined sensorimotor system\n* Alcohol abuse\n* Severe psychiatric disorders (e.g., schizophrenia)\n* Any tumor disease with a life expectancy of \\\u003C1 year\n* Increased intracranial pressure\n* Patients with a medical device containing electronics or conductive materials\n* Patients on continuous oxygen (system not adapted)",{"count":73,"type":20},60,[23],"This is a prospective clinical study to evaluate the efficacy of tDCS stimulation, coupled with conventional rehabilitation, on the development of post-stroke neuropathic pain.\n\nThe study involves a double-blind, randomized, sham-controlled experimental protocol involving 2 parallel groups with patients allocated according to a Fleming design (40 patients in the active group, 20 patients in the control group).\n\nThe study is aimed at sub-acute post-stroke patients. After recruitment, they will receive 10 sessions of tDCS stimulation (2mA, 20 minutes with a current on\u002Foff ramp of 0.1 mA\u002Fs). For the control group, stimulation will stop after the current ramp.",[77,54,78],"Stroke","Central Post Stroke Pain",[80,81,82,83,84,85],"neuropathic pain","prevention","stroke","central post stroke pain","neuromodulation","tDCS","NOT_YET_RECRUITING","2025-12-17",{"date":89,"type":31},"2025-12-23",{"date":91,"type":20},"2026-01-01",{"date":93,"type":20},"2029-04-30",{"name":95,"class":64},"University Hospital, Clermont-Ferrand",2,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":39},"100545899","efficacy-of-pain-intervention-with-deep-brain-stimulation-neuromodulation-100545899","NCT06387914","Efficacy of Pain Intervention With Deep Brain Stimulation Neuromodulation","EPIONE","Inclusion criteria\n\nA patient will be eligible for inclusion in this trial if all of the following criteria apply:\n\n* Willing and able to give informed consent for participation in the trial.\n* Willing and able to follow pre and post-operative procedures in Oxford.\n* Aged 21 years or above.\n* Diagnosed as having central post stroke pain of 2 years' minimum duration refractory to best medical\u002Fnon-medical treatment\n* Mean usual VAS (or NRS) pain score \\> 6\u002F10 despite input from a multidisciplinary pain team.\n\nExclusion criteria\n\nA patient will not be eligible for the trial if any of the following apply:\n\n* Contraindication for elective general anaesthesia, for example but not limited to severe cardiovascular disease, hyponatraemia, hyperkalaemia, etc.\n* Previous implantation of a DBS device with device still in situ.\n* Contraindication to MRI\n* Contraindication to neurosurgery, e.g. Bleeding disorders, not able to stop anticoagulation safely for perioperative phase (approx. 10 days, 5 days pre-operatively, 5 days postoperatively) Major psychiatric or cognitive disorder that may affect mental capacity that is untreated or may otherwise affect the participant's ability to engage in the trial\n* Active skin-based infection or colonisation with a multi-drug resistant organism e.g. methicillin-resistant Staphylococcus aureus (MRSA)\n* Requires regular MRI investigations post-operatively\n* Likely to require diathermy, ultrasound or transcranial magnetic stimulation post DBS device insertion\n* Not tolerant of awake surgery\n* Unable to cooperate with device recharging\n* Pregnancy or planned pregnancy\n* In the investigator's opinion unable to comply with the protocol","21 Years",{"count":106,"type":20},30,[23],"The goal of this clinical trial is to learn if deep brain stimulation (DBS) works to treat severe pain following a stroke in adults. It will also learn about the safety of deep brain stimulation. The main questions it aims to answer are:\n\n* Does DBS lower the pain score in these participants.\n* What medical problems do participants have when having DBS? Researchers will compare different settings, to see if DBS works to treat severe post stroke pain.\n\nParticipants will:\n\n* Undergo baseline screening procedures and have an MRI scan.\n* Have neurosurgery to put the DBS system in\n* Have follow up for 10 months\n* Visit the clinic at least 5 times in the study for check-ups and tests\n* Fill in questionnaires about pain and mood and have check ups remotely",[78],[111,112,78,113,114,115],"Deep Brain Stimulation","Neuropathic pain","Randomised Controlled Trial","Sensory thalamus","Periaqueductal Gray","2025-11-14",{"date":118,"type":31},"2025-11-19",{"date":120,"type":31},"2024-08-07",{"date":122,"type":20},"2028-12",{"name":124,"class":64},"University of Oxford",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":39},"100493713","neuromodulation-for-central-post-stroke-pain-mechanism-safety-and-outcome-100493713","NCT05708729","Neuromodulation for Central Post-stroke Pain: Mechanism, Safety and Outcome","Inclusion Criteria:\n\n1. Able to provide voluntary written informed consent of the participant prior to any screening procedures\n2. Male or female patients\n3. Aged 18-70 years\n4. Diagnosed with definite CPSP (Treede-Klit criteria) (1, 9), which is pharmacorefractory (i.e. amitriptyline 75mg\u002Fd 4w, lamotrigine 200mg\u002Fd 8w and pregabalin 600mg\u002Fd resulting in \\\u003C50% VAS reduction and\u002For intolerable side-effects)\n\nExclusion Criteria:\n\n1. Aphasia\n2. Pregnancy or intention to become pregnant in the following year\n3. Medical inoperability\n4. Impossibility to temporarily withhold anticoagulation or anti-platelet medication\n5. Impossibility to undergo MRI, fMRI and\u002For PET imaging\n6. Complete destruction of the stimulation target region (M1 or Vc)\n7. Uncontrolled seizures\n8. Expected relocation in the following year.","70 Years",{"count":133,"type":20},32,[23],"Central post-stroke pain (CPSP) is an often pharmacorefractory type of neuropathic pain that develops in 8% of stroke patients. CPSP has been treated with three distinct types of neuromodulation (deep brain stimulation of the sensory thalamus (Vc-DBS), motor cortex repetitive transcranial magnetic stimulation (M1-rTMS), and motor cortex stimulation (MCS)), but the level of evidence for these procedures is very low. Moreover, data on the changes in pain brain circuitry in CPSP, and the effect of neuromodulation on this circuitry is very limited.",[53,137],"CPSP",[84,139,140,141],"DBS","rTMS","MCS","2024-06-28",{"date":144,"type":31},"2024-07-01",{"date":146,"type":31},"2023-01-24",{"date":148,"type":20},"2026-04",{"name":150,"class":64},"Universitaire Ziekenhuizen KU Leuven"]